Literature DB >> 27019050

Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).

Ying Sun1, Weici Zhang2, Jilly F Evans3, Annarosa Floreani4, Zhengsheng Zou5, Yukiko Nishio6, Ruizhao Qi7, Patrick S C Leung8, Christopher L Bowlus9, M Eric Gershwin10.   

Abstract

Autotaxin (ATX) is a 125-kD type II ectonucleotide pyrophosphatase/phosphodiesterase (ENPP2 or NPP2) originally discovered as an unknown "autocrine motility factor" in human melanoma cells. In addition to its pyrophosphatase/phosphodiesterase activities ATX has lysophospholipase D (lysoPLD) activity, catalyzing the conversion of lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). ATX is the only ENPP family member with lysoPLD activity and it produces most of the LPA in circulation. In support of this, ATX heterozygous mice have 50% of normal LPA plasma levels. The ATX-LPA signaling axis plays an important role in both normal physiology and disease pathogenesis and recently has been linked to pruritus in chronic cholestatic liver diseases, including primary biliary cholangitis (PBC). Several lines of evidence have suggested that a circulating puritogen is responsible, but the identification of the molecule has yet to be definitively identified. In contrast, plasma ATX activity is strongly associated with pruritus in PBC, suggesting a targetable molecule for treatment. We review herein the biochemistry of ATX and the rationale for its role in pruritus.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autotaxin; autoimmunity; cholestatic liver diseases; lysophosphatidylcholine; pruritus

Mesh:

Substances:

Year:  2016        PMID: 27019050     DOI: 10.1016/j.autrev.2016.03.019

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  9 in total

Review 1.  Immunology of hepatic diseases during pregnancy.

Authors:  Lars Bremer; Christoph Schramm; Gisa Tiegs
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

2.  Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.

Authors:  Minami Yagi; Atsushi Tanaka; Tadashi Namisaki; Atsushi Takahashi; Masanori Abe; Akira Honda; Yasushi Matsuzaki; Hiromasa Ohira; Hitoshi Yoshiji; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-04-16       Impact factor: 7.527

3.  Cholestatic pruritus: Emerging mechanisms and therapeutics.

Authors:  Sagar P Patel; Chirag Vasavda; Byron Ho; James Meixiong; Xinzhong Dong; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

Review 4.  Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Rheumatol Ther       Date:  2017-08-08

5.  Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis.

Authors:  Minami Yagi; Atsushi Tanaka; Masanori Abe; Tadashi Namisaki; Hitoshi Yoshiji; Atsushi Takahashi; Hiromasa Ohira; Atsumasa Komori; Satoshi Yamagiwa; Kentaro Kikuchi; Tetsuya Yasunaka; Akinobu Takaki; Yoshiyuki Ueno; Akira Honda; Yasushi Matsuzaki; Hajime Takikawa
Journal:  Sci Rep       Date:  2018-08-22       Impact factor: 4.379

Review 6.  Recent advances in the diagnosis and treatment of primary biliary cholangitis.

Authors:  Ying-Qiu Huang
Journal:  World J Hepatol       Date:  2016-11-28

Review 7.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

8.  Toward solving the etiological mystery of primary biliary cholangitis.

Authors:  Atsushi Tanakaa; Patrick Sc Leung; Howard A Young; M Eric Gershwin
Journal:  Hepatol Commun       Date:  2017-05-18

Review 9.  Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents.

Authors:  Sho Hasegawa; Masato Yoneda; Yusuke Kurita; Asako Nogami; Yasushi Honda; Kunihiro Hosono; Atsushi Nakajima
Journal:  Drugs       Date:  2021-06-17       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.